Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Zongting Gu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7800-7988; OpenAlex author ID A5031592759. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2020: 1 paper · 2021: 3 papers · 2022: 6 papers · 2023: 3 papers · 2024: none · 2025: 4 papers

Papers 17

  1. Delayed gastric emptying risk stratification in patients with pancreatic ductal adenocarcinoma after pancreatoduodenectomy: An international validation cohort … Co-author DOI 10.1002/ueg2.12688↗
  2. STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. Co-author DOI 10.1007/s00535-025-02291-3↗
  3. TSPAN15 sustains ITGB1 stability to block gemcitabine-induced ferroptosis in pancreatic ductal adenocarcinoma through the FAK/AKT/Mtor-gpx4 cascade. Co-author DOI 10.1016/j.redox.2025.103721↗
  4. Diagnostic performance of artificial intelligence models in predicting liver metastasis in pancreatic ductal adenocarcinoma (PDAC): a systematic review and met… Last author DOI 10.1097/js9.0000000000004425↗
  5. Expression, prognostic value and mechanism of SP100 family in pancreatic adenocarcinoma. Co-author DOI 10.18632/aging.204811↗
  6. Subcellular localization of nucleolar protein 14 and its proliferative function mediated by miR-17-5p and E2F4 in pancreatic cancer. Co-author DOI 10.18632/aging.204915↗
  7. An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma. First author DOI 10.31083/j.fbl2812361↗
  8. Dynamic Interplay between Structural Variations and 3D Genome Organization in Pancreatic Cancer. First author DOI 10.1002/advs.202200818↗
  9. A new era: tumor microenvironment in chemoresistance of pancreatic cancer. Last author DOI 10.26502/jcsct.5079146↗
  10. Expression, Prognostic Value, and Functional Mechanism of the KDM5 Family in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2022.887385↗
  11. Prognostic value, immune signature and molecular mechanisms of the APOBEC family members APOBEC1, APOBEC3A, APOBEC3G and APOBEC3H in pancreatic adenocarcinoma. Co-author DOI 10.3389/fmolb.2022.1036287↗
  12. Prognostic value, immune signature and molecular mechanisms of the SUMO family in pancreatic adenocarcinoma. Co-author DOI 10.3389/fmolb.2022.1096679↗
  13. Prognostic Value, Immune Signature, and Molecular Mechanisms of the PHLDA Family in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/ijms231810316↗
  14. Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.08.029↗
  15. Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.04.007↗
  16. Preoperative Alkaline Phosphatase-to-Cholesterol Ratio as a Predictor of Overall Survival in Pancreatic Ductal Adenocarcinoma Patients Undergoing Radical Pancr… Co-author DOI 10.12659/msm.931868↗
  17. Over-expression of ANP32E is associated with poor prognosis of pancreatic cancer and promotes cell proliferation and migration through regulating β-catenin. Co-author DOI 10.1186/s12885-020-07556-z↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongxing Du · 11 shared papers, 2021–2025 · strength 2.16
  2. Yunjie Duan · 7 shared papers, 2022–2025 · strength 1.55
  3. Xiaohao Zheng · 6 shared papers, 2022–2025 · strength 1.27
  4. Chengfeng Wang · 5 shared papers, 2020–2023 · strength 0.91
  5. Chengfeng Wang · 3 shared papers, 2022–2025 · strength 0.74
  6. Peng Nan · 2 shared papers, 2025 · strength 0.54
  7. Ran Tao · 2 shared papers, 2023–2025 · strength 0.50
  8. Xueping Zhao · 2 shared papers, 2021–2022 · strength 0.45
  9. Yichen Wu · 1 shared paper, 2025 · strength 0.42
  10. Chengfeng Wang · 3 shared papers, 2021–2022 · strength 0.42
  11. Hu Ren · 3 shared papers, 2020–2021 · strength 0.37
  12. Guotong Qiu · 3 shared papers, 2020–2021 · strength 0.37
  13. Jianwei Zhang · 1 shared paper, 2025 · strength 0.30
  14. Xiao Wang · 1 shared paper, 2025 · strength 0.28
  15. Lipeng Zhang · 2 shared papers, 2021 · strength 0.26
  16. Ran Tao · 1 shared paper, 2025 · strength 0.26
  17. Xiao Wang · 1 shared paper, 2025 · strength 0.26
  18. Wei Wang · 1 shared paper, 2025 · strength 0.26
  19. Jianwei Zhang · 2 shared papers, 2020–2021 · strength 0.22
  20. Tianpeng Zhang · 1 shared paper, 2023 · strength 0.22
  21. Ran Ni · 1 shared paper, 2023 · strength 0.22
  22. Yefeng Yin · 1 shared paper, 2023 · strength 0.20
  23. Chengfeng Wang · 1 shared paper, 2022 · strength 0.20
  24. Hebing Chen · 1 shared paper, 2022 · strength 0.16
  25. Ke Xu · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.